First Author: A.Liaska GREECE
Co Author(s): T. Pallantzas E. Makri V. Dimopoulou S. Stamelou K. Andrianopoulou 0 0 0 0 0 0 0 0 0
Back to previous
in patients with neovascular(age-related) macular degeneration(n-AMD)on anti-vascular-endothelial-growth-factor(anti-VEGF) treatment, disease activity may last for years. Criteria as total number of injections or duration of treatment as used to stop reimbursement of anti-VE GF treatment are not related to disease activity while the prerequisite of visual acuity better or equal to 1/10 may exclude from treatment patients who still have the potential of visual improvement. In the present study we examine the clinical course of eyes with n-AMD after visual acuity drops below 1/10 or/and duration of treatment over 3 years in comparison to the fellow eye suffering from end-stage disease(macular scar).
Department of Ophthalmology, General Hospital of Lamia, Lamia, GREECE
retrospective, case series. 5 patients (3 men, 2 women) age 82-90 years, with active n-AMD in one eye and macular scar (end-stage n-AMD) in the fellow eye (natural course of the disease) continued the anti-VEGF treatment in relation to disease activity after visual acuity dropped below 1/10 and/or beyond 3 years of anti-VEGF treatment , until the disease became inactive for at least 3 months. Aparametric methods were used to compare the results in both eyes. All patients were addressed the question which eye they considered as “seeing”.
the final visual acuity in the treated eyes was 1/40-2/10 while in the fellow eyes was Hand Movement to Counting Fingers (1 m) (p=0.0422, Wilcoxon signed rank sum test). The size of the lesion was 1-2 disc diameters in the treated eyes while in the fellow eyes occupied the whole area between the temporal vascular arcades (p=0.0253, Wilcoxon signed rank sum test). In questionnaire all patients described as “seeing” the treated eye.
continuation of anti-VEGF treatment in eyes with low vision and active disease may preserve useful vision and thus possibly contributing in quality of life of patients with neovascular age-related macular degeneration.